ArcaArca
Dashboard
All boards
Loading...
PatientsTasksProgram PerformanceRegistry
Settings
  1. Home
  2. Tumor Boards
  3. Board
  4. Session

Breast Oncology Tumor Board

Sat, May 2, 2026 · 07:30 · Conference Room A

In Progress
0
Case 1 of 10 · 0 discussed

0 of 10 presented

Li, Chioma

MRN-001004·53y

Presenting

Dr. James Wilson

Invasive Ductal Carcinoma, HR+/HER2-·Stage IB
BiomarkersER+/PR+/HER2− · Ki-67 24%
HistologyInvasive ductal carcinoma · Grade G2
Path StagepT1N1M0
MarginsNegative
Key LabsHemoglobin 12.2Platelets 111
Prior TxPostmenopausal

Highlighted Path

Li, Chioma

Invasive ductal carcinoma · Stage IB · ER+/PR+/HER2-, Ki-67 24%, Oncotype DX RS 18

NCCN Breast Cancer

v4.2025

Breast Cancer
DCIS (Non-invasive)
Stage 0
Lumpectomy → ± WBRT → ± Endocrine
Mastectomy → ± Endocrine
Invasive
Early Stage (I–IIA)
HR+/HER2−
Surgery → Endocrine ± Chemo
HR+/HER2+
Surgery → TCH(P) → Endocrine
HR−/HER2+
Surgery → TCH(P)
Triple Negative
Surgery → AC-T
Locally Advanced (IIB–III)
HR+/HER2−
Neoadjuvant Chemo → Surgery → Endocrine
HER2+
Neoadjuvant TCHP → Surgery → HER2 maintenance
Triple Negative
Neoadjuvant Chemo + Pembrolizumab → Surgery
Metastatic (IV)
HR+/HER2−
Endocrine + CDK4/6i (1L)
HER2+
Taxane + Trastuzumab + Pertuzumab (1L)
Triple Negative
Chemo + Pembrolizumab (PD-L1+)
Patient pathway Other pathways
12 treatment approaches mapped
Case 1 of 1000:00
Clinical question

Oncotype DX recurrence score borderline — systemic chemotherapy benefit vs. endocrine therapy alone.

Loading guidelines…
Owner
0 recommendations confirmed